San Jose, California, November 1, 2018 – Molecular Devices announced today the launch of the new SoftMax® Pro 7.1 GxP Software with complete validation tools which achieves full FDA 21 CFR Part 11 compliance in GMP/GLP labs.
Built on its current, industry-leading data acquisition and analysis software, SoftMax Pro 7.1 GxP Software expands its system audit trail functions to include date and time stamps; enables enterprise-level document sharing with Microsoft SQL database; provides complete control over file access permissions; and maintains data integrity with eSignatures and document workflows.
“Being compliant has never been more important to our customers”, said Greg Milosevich, President of Molecular Devices. “We will partner with you to set up single- or enterprise-level software and provide IQOQ services to establish full compliance on your microplate readers. Major data privacy and security improvements support the latest GDPR regulations.”
About Molecular Devices, LLC
Molecular Devices is one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.
For more information, visit: